Innoveren Scientific Inc. · OTC:IVRN
Innoveren Scientific — Medovex — Investor Presentation (August 2017)
21 slides from Innoveren Scientific's investor presentation, Aug 9, 2017
Slide 1: Investor Presentation
fMEDOVEX Investor Presentation | a iit 2017 nrs000- wove a
Slide 2: Safe Harbor
Safe Harbor I MEDOvEX
Slide 3: About Medovex
About Medovex was formed to acquire and develop a diversified portfolio of potentially ground Medovex breaking medical technology products. * Disruptive flagship device, Denervex™ System, targets large segment of $78 osteoarthritis market opportunity * First units shipped to Germany, UK and Italy *
Slide 4: Significant Med-Tech Background
Significant Med-Tech Background Acombined 100+ years of management experience Jarrett Gorlin Jeffrey Wright, CPA Patrick Kullmann, Chief Executive Officer Chief Financial Officer President & Board of Directors: Chief Operating Officer Steve Gorlin Larry Papasan Scott Haufe, MD Co-Founder Chairman In
Slide 5: Facet Joint Syndrome
Facet Joint Syndrome Causes Pain When Facet Joints are Injured or Degenerate I MEDovEX
Slide 6: Chronic back pain and facet joint syndrome prevalence
of all adults suffer from chronic back pain’ @c 18% Pain 31% Of back pain is due to Facet Joint Syndrome Major Sources of Back Pain? ae, Internal Dise Disruption XMepovex
Slide 7: $7.0B DenerveX addressable market opportunity
NE He $7.0B Opportunity* DenerveX Total —* $4.6B DenerveX OUS Market Addressable Market (eee DenerveX US Addressable Market 2 Mepovex
Slide 8: Current Treatment Options
Current Treatment Options Effective but temporary Injections RF Ablation Effective for 0-3 Months Effective for 6-12 Months
Slide 9: DenerveX System: Tissue Ablation and Scraping in One Device
DenerveX System: Tissue Ablation and Scraping in One Device Aparadigm shift in FJS. treatment MEDOVEX
Slide 10: DenerveX System Treatment Area
DenerveX System Treatment Area The DenerveX system delivers enduring relief by treating a larger area and removing a Synovial portion of the joint Capsule sul —_ Standard RF Ablation Area 2 Mepovex to
Slide 11: Tissue Removal & Ablation: The DenerveX Method
Tissue Removal & Ablation: The DenerveX Manual Method Concept Ablate the medial nerve while removing a portion of the joint capsule, preventing nerve reattachment or regeneration 75% Of patients reported a 50% or greater improvement in VAS pain scores and ODI disability scores at 3 years. I MEDovEX
Slide 12: Change in FJS Pain Following Treatment
Change in FJS Pain Following Treatment 68% DenerveX method is designed to be more effective than the alternatives Denervex MEDOVEX RF Ablation! Injections:
Slide 13: Relief Duration Following a Single Treatment
Relief Duration Following a Single Treatment 3 Years DenerveX Method Is intended to reduce or eliminate pain for at least 3 Years 6-12 Months Denervex RF Ablation _ Injections MEDOVEX
Slide 14: Cost of Treatment for Three Years
Cost of Treatment for 3 Years $12,900 DenerveX is Expected to Significantly Reduce the Total Cost of Care for FJS Patients Over a Three Year Period RF Ablation —_ Injections (One Treatment) 6 (8 Injections) Treatments) MEDOVEX, 14
Slide 15: Build Market Awareness
+ Build Market Awareness Geographic expansion according Ss uccess “S staged rollout launch plan Drivers + Increased distributor relationships + Development of clinical evidence Mepovex
Slide 16: Market Awareness: first in-human case and training
[iors TR Gooorphic Exansion MAL Osrbvir Rottonshire UMMM Civica! Evidence | Market Awareness I MEDovEX First In-Human Case July 11, 2017 Physician and Distributor Training in Germany/U.K./italy Physician trainee observation of 2-3 Cases Supervision for 2 Further Cases, then Certified Use of cadaver
Slide 17: Multi-Stage Global Launch Strategy
> as > EE Multi-Stage Global Launch Strategy Timing _ Countries Di Pitot 3017 Germany, UK. Stage 1 4017 Ireland, Spain, Australia, New Zealand 11M Turkey, Denmark, Sweden, Norway, Finland, Israel, Stage 2 1018 italy, Netherlands, Austria, Colombia, 30M Belgium, Luxemburg, Greece, Portugal, Poland, S
Slide 18: Distributor Relationships
| srt Anoroness LI Goooraphic Expansion MARI Otc cunicosncs MRAM Cini evince | Distributor Relationships + Established relationships with 12 initial distributors across 19 countries + Customer-focused device designed by and for physicians eases distributor marketing burden + Selective vetting proces
Slide 19: Clinical Evidence Strategy
| srt Anoroness EI Goooraphic Expansion EI OisibiorReasonsins MLM Coon | ical Evidence Strategy + Develop initial marketing case studies based on initial clinical ‘outcomes + Create a clinical campaign surrounding the first use of a novel approach to treatment of FJS + Formal registry in Europe for
Slide 20: Summary
Summary Commercialized DenerveX System for Facet Joint Syndrome + Paradigm shift in FUS treatment + 180 13485 certification + Regulatory approval with CE Mark in Europe + Significant benefits to current standard of care + S7.0B Addressable Market Global Rollout + Launched in key geographic areas, ne
Slide 21: Thank You